

# **EXHIBIT J**

## **Part 1 of 2**

SOLE INVENTOR

**APPLICATION FOR  
UNITED STATES LETTERS PATENT**

**SPECIFICATION**

---

TO ALL WHOM IT MAY CONCERN:

Be it known that I, FU-KUEN LIN

a citizen of the United States, residing at 438 Thunderhead Street, Thousand Oaks,

in the County of Ventura and State of California

have invented a new and useful "PRODUCTION OF ERYTHROPOIETIN"

of which the following is a specification.

AM 27 013949

- 1 -

"PRODUCTION OF ERYTHROPOIETIN"

"Prel."

a continuation of my co-pending U.S. Patent App. Serial NO 655,841  
This is a continuation-in-part of my co-pending U.S. Patent Application Serial Nos. 561,024, filed December 13, 1983, 582,185, filed February 21, 1984, and 655,841, filed September 28, 1984. *filed 4/30/84 which is in turn*

BACKGROUND

10 The present invention relates generally to the manipulation of genetic materials and, more particularly, to recombinant procedures making possible the production of polypeptides possessing part or all of the primary structural conformation and/or one or more of the biological properties of naturally-occurring erythropoietin.

A. Manipulation Of Genetic Materials

Genetic materials may be broadly defined as those chemical substances which program for and guide the manufacture of constituents of cells and viruses and direct the responses of cells and viruses. A long chain polymeric substance known as deoxyribonucleic acid (DNA) comprises the genetic material of all living cells and viruses except for certain viruses which are programmed by ribonucleic acids (RNA). The repeating units in DNA polymers are four different nucleotides, each of which consists of either a purine (adenine or guanine) or a pyrimidine (thymine or cytosine) bound to a deoxyribose sugar to which a phosphate group is attached. Attachment of nucleotides in linear polymeric form is by means of fusion of the 5' phosphate of one nucleotide to the 3' hydroxyl group of another. Functional DNA occurs in the form of stable double stranded associations of single strands of nucleotides (known as deoxyoligonucleotides),

AM 27 013950

AM-ITC 00453886

- 2 -

which associations occur by means of hydrogen bonding between purine and pyrimidine bases [i.e., "complementary" associations existing either between adenine (A) and thymine (T) or guanine (G) and cytosine (C)]. By convention, nucleotides are referred to by the names of their constituent purine or pyrimidine bases, and the complementary associations of nucleotides in double stranded DNA (i.e., A-T and G-C) are referred to as "base pairs". Ribonucleic acid is a polynucleotide comprising adenine, guanine, cytosine and uracil (U), rather than thymine, bound to ribose and a phosphate group.

Most briefly put, the programming function of DNA is generally effected through a process wherein specific DNA nucleotide sequences (genes) are "transcribed" into relatively unstable messenger RNA (mRNA) polymers. The mRNA, in turn, serves as a template for the formation of structural, regulatory and catalytic proteins from amino acids. This mRNA "translation" process involves the operations of small RNA strands (tRNA) which transport and align individual amino acids along the mRNA strand to allow for formation of polypeptides in proper amino acid sequences. The mRNA "message", derived from DNA and providing the basis for the tRNA supply and orientation of any given one of the twenty amino acids for polypeptide "expression", is in the form of triplet "codons" -- sequential groupings of three nucleotide bases. In one sense, the formation of a protein is the ultimate form of "expression" of the programmed genetic message provided by the nucleotide sequence of a gene.

"Promoter" DNA sequences usually "precede" a gene in a DNA polymer and provide a site for initiation of the transcription into mRNA. "Regulator" DNA sequences, also usually "upstream" of (i.e., preceding) a gene in a given DNA polymer, bind proteins that determine the frequency (or rate) of transcriptional initiation.

AM 27 013951

AM-ITC 00453887

- 3 -

Collectively referred to as "promoter/regulator" or "control" DNA sequence, these sequences which precede a selected gene (or series of genes) in a functional DNA polymer cooperate to determine whether the transcription  
5 (and eventual expression) of a gene will occur. DNA sequences which "follow" a gene in a DNA polymer and provide a signal for termination of the transcription into mRNA are referred to as transcription "terminator" sequences.

10 A focus of microbiological processing for the last decade has been the attempt to manufacture industrially and pharmaceutically significant substances using organisms which either do not initially have genetically coded information concerning the desired product  
15 included in their DNA, or (in the case of mammalian cells in culture) do not ordinarily express a chromosomal gene at appreciable levels. Simply put, a gene that specifies the structure of a desired polypeptide product is either isolated from a "donor" organism or chemically synthesized and then stably introduced into another organism  
20 which is preferably a self-replicating unicellular organism such as bacteria, yeast or mammalian cells in culture. Once this is done, the existing machinery for gene expression in the "transformed" or "transfected" microbial host cells operates to construct the desired  
25 product, using the exogenous DNA as a template for transcription of mRNA which is then translated into a continuous sequence of amino acid residues.

The art is rich in patent and literature publications relating to "recombinant DNA" methodologies for  
30 the isolation, synthesis, purification and amplification of genetic materials for use in the transformation of selected host organisms. U.S. Letters Patent No. 4,237,224 to Cohen, et al., for example, relates to  
35 transformation of unicellular host organisms with "hybrid" viral or circular plasmid DNA which includes

AM 27 013952

AM-ITC 00453888

- 4 -

selected exogenous DNA sequences. The procedures of the Cohen, et al. patent first involve manufacture of a transformation vector by enzymatically cleaving viral or circular plasmid DNA to form linear DNA strands.

- 5 Selected foreign ("exogenous" or "heterologous") DNA strands usually including sequences coding for desired product are prepared in linear form through use of similar enzymes. The linear viral or plasmid DNA is incubated with the foreign DNA in the presence of ligating enzymes capable of effecting a restoration process and "hybrid" vectors are formed which include the selected exogenous DNA segment "spliced" into the viral or circular DNA plasmid.

- 10 Transformation of compatible unicellular host organisms with the hybrid vector results in the formation of multiple copies of the exogenous DNA in the host cell population. In some instances, the desired result is simply the amplification of the foreign DNA and the "product" harvested is DNA. More frequently, the goal of transformation is the expression by the host cells of the exogenous DNA in the form of large scale synthesis of isolatable quantities of commercially significant protein or polypeptide fragments coded for by the foreign DNA. See also, e.g., U.S. Letters Patent Nos. 4,264,731 (to Shine), 4,273,875 (to Manis), 4,293,652 (to Cohen), and European Patent Application 093,619, published November 9, 1983.

- 20 The development of specific DNA sequences for splicing into DNA vectors is accomplished by a variety of techniques, depending to a great deal on the degree of "foreignness" of the "donor" to the projected host and the size of the polypeptide to be expressed in the host. At the risk of over-simplification, it can be stated that three alternative principal methods can be employed: (1) the "isolation" of double-stranded DNA sequence from the genomic DNA of the donor; (2) the chemical manufacture of

AM 27 013953

AM-ITC 00453889

- 5 -

a DNA sequence providing a code for a polypeptide of interest; and (3) the in vitro synthesis of a double-stranded DNA sequence by enzymatic "reverse transcription" of mRNA isolated from donor cells. The  
5 last-mentioned methods which involve formation of a DNA "complement" of mRNA are generally referred to as "cDNA" methods.

Manufacture of DNA sequences is frequently the method of choice when the entire sequence of amino acid  
10 residues of the desired polypeptide product is known. DNA manufacturing procedures of co-owned, co-pending U.S. Patent Application Serial No. 483,451, by Alton, et al., (filed April 15, 1983 and corresponding to PCT  
US83/00605, published November 24, 1983 as WO83/04053),  
15 for example, provide a superior means for accomplishing such highly desirable results as: providing for the presence of alternate codons commonly found in genes which are highly expressed in the host organism selected for expression (e.g., providing yeast or E.coli "preference"  
20 codons); avoiding the presence of untranslated "intron" sequences (commonly present in mammalian genomic DNA sequences and mRNA transcripts thereof) which are not readily processed by procaryotic host cells; avoiding expression of undesired "leader" polypeptide sequences  
25 commonly coded for by genomic DNA and cDNA sequences but frequently not readily cleaved from the polypeptide of interest by bacterial or yeast host cells; providing for ready insertion of the DNA in convenient expression vectors in association with desired promoter/regulator and  
30 terminator sequences; and providing for ready construction of genes coding for polypeptide fragments and analogs of the desired polypeptides.

When the entire sequence of amino acid residues of the desired polypeptide is not known, direct manufacture of DNA sequences is not possible and isolation of  
35 DNA sequences coding for the polypeptide by a cDNA method

AM 27 013954

AM-ITC 00453890

- 6 -

becomes the method of choice despite the potential drawbacks in ease of assembly of expression vectors capable of providing high levels of microbial expression referred to above. Among the standard procedures for

5 isolating cDNA sequences of interest is the preparation of plasmid-borne cDNA "libraries" derived from reverse transcription of mRNA abundant in donor cells selected as responsible for high level expression of genes (e.g., libraries of cDNA derived from pituitary cells which

10 express relatively large quantities of growth hormone products). Where substantial portions of the polypeptide's amino acid sequence are known, labelled, single-stranded DNA probe sequences duplicating a sequence putatively present in the "target" cDNA may be employed

15 in DNA/DNA hybridization procedures carried out on cloned copies of the cDNA which have been denatured to single stranded form. [See, generally, the disclosure and discussions of the art provided in U.S. Patent No. 4,394,443 to Weissman, et al. and the recent demonstrations of the use of long oligonucleotide hybridization

20 probes reported in Wallace, et al., Nuc.Acids Res., 6, pp. 3543-3557 (1979), and Reyes, et al., P.N.A.S. (U.S.A.), 79, pp. 3270-3274 (1982), and Jaye, et al., Nuc.Acids Res., 11, pp. 2325-2335 (1983). See also, U.S.

25 Patent No. 4,358,535 to Falkow, et al., relating to DNA/DNA hybridization procedures in effecting diagnosis; published European Patent Application Nos. 0070685 and 0070687 relating to light-emitting labels on single stranded polynucleotide probes; Davis, et al., "A Manual

30 for Genetic Engineering, Advanced Bacterial Genetics", Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1980) at pp. 55-58 and 174-176, relating to colony and plaque hybridization techniques; and, New England Nuclear (Boston, Mass.) brochures for "Gene Screen" Hybridization

35 Transfer Membrane materials providing instruction manuals for the transfer and hybridization of DNA and RNA, Catalog No. NEF-972.]

AM 27 013955



- 7 -

Among the more significant recent advances in hybridization procedures for the screening of recombinant clones is the use of labelled mixed synthetic oligonucleotide probes, each of which is potentially the complete complement of a specific DNA sequence in the hybridization sample including a heterogeneous mixture of single stranded DNAs or RNAs. These procedures are acknowledged to be especially useful in the detection of cDNA clones derived from sources which provide extremely low amounts of mRNA sequences for the polypeptide of interest. Briefly put, use of stringent hybridization conditions directed toward avoidance of non-specific binding can allow, e.g., for the autoradiographic visualization of a specific cDNA clone upon the event of hybridization of the target DNA to that single probe within the mixture which is its complete complement. See generally, Wallace, et al., Nuc.Acids Res., 9, pp. 879-897 (1981); Suggs, et al. P.N.A.S. (U.S.A.), 78, pp. 6613-6617 (1981); Choo, et al., Nature, 299, pp. 178-180 (1982); Kurachi, et al., P.N.A.S. (U.S.A.), 79, pp. 6461-6464 (1982); Ohkubo, et al., P.N.A.S. (U.S.A.), 80, pp. 2196-2200 (1983); and Kornblihtt, et al. P.N.A.S. (U.S.A.), 80, pp. 3218-3222 (1983). In general, the mixed probe procedures of Wallace, et al. (1981), supra, have been expanded upon by various workers to the point where reliable results have reportedly been obtained in a cDNA clone isolation using a 32 member mixed "pool" of 16-base-long (16-mer) oligonucleotide probes of uniformly, varying DNA sequences together with a single 11-mer to effect a two-site "positive" confirmation of the presence of cDNA of interest. See, Singer-Sam, et al., P.N.A.S. (U.S.A.), 80, pp. 802-806 (1983).

The use of genomic DNA isolates is the least common of the three above-noted methods for developing

AM 27 013956

AM-ITC 00453892

- 8 -

specific DNA sequences for use in recombinant procedures. This is especially true in the area of recombinant procedures directed to securing microbial expression of mammalian polypeptides and is due, principally to the

5 complexity of mammalian genomic DNA. Thus, while reliable procedures exist for developing phage-borne libraries of genomic DNA of human and other mammalian species origins [See, e.g., Lawn, et al. Cell, 15, pp. 1157-1174 (1978) relating to procedures for

10 generating a human genomic library commonly referred to as the "Maniatis Library"; Karn, et al., P.N.A.S. (U.S.A.), 77, pp. 5172-5176 (1980) relating to a human genomic library based on alternative restriction endonuclease fragmentation procedure; and Blattner, et al.,

15 Science, 196, pp. 161-169 (1977) describing construction of a bovine genomic library] there have been relatively few successful attempts at use of hybridization procedures in isolating genomic DNA in the absence of extensive foreknowledge of amino acid or DNA sequences. As

20 one example, Fiddes, et al., J.Mol. and App.Genetics, 1, pp. 3-18 (1981) report the successful isolation of a gene coding for the alpha subunit of the human pituitary glycoprotein hormones from the Maniatis Library through use of a "full length" probe including a complete 621 base

25 pair fragment of a previously-isolated cDNA sequence for the alpha subunit. As another example, Das, et al., P.N.A.S. (U.S.A.), 80, pp. 1531-1535 (1983) report isolation of human genomic clones for human HLA-DR using a 175 base pair synthetic oligonucleotide. Finally, Anderson,

30 et al., P.N.A.S. (U.S.A.), 80, pp. 6838-6842 (1983) report the isolation of genomic clone for bovine pancreatic trypsin inhibitor (BPTI) using a single probe 86 base pairs in length and constructed according to the known amino acid sequence of BPTI. The authors note a

35 determination of poor prospects for isolating mRNA suitable for synthesis of a cDNA library due to apparent

AM 27 013957

AM-ITC 00453893

- 9 -

low levels of mRNA in initially targeted parotid gland and lung tissue sources and then address the prospects of success in probing a genomic library using a mixture of labelled probes, stating: "More generally, mixed-

5 sequence oligodeoxynucleotide probes have been used to isolate protein genes of unknown sequence from cDNA libraries. Such probes are typically mixtures of 8-32 oligonucleotides, 14-17 nucleotides in length, representing every possible codon combination for a small

10 stretch (5-6 residues) of amino acid sequence. Under stringent hybridization conditions that discriminate against incorrectly base-paired probes, these mixtures are capable of locating specific gene sequences in clone libraries of low-to-moderate complexity. Nevertheless,

15 because of their short length and heterogeneity, mixed probes often lack the specificity required for probing sequences as complex as a mammalian genome. This makes such a method impractical for the isolation of mammalian protein genes when the corresponding mRNAs are

20 unavailable." (Citations omitted).

There thus continues to exist a need in the art for improved methods for effecting the rapid and efficient isolation of cDNA clones in instances where little is known of the amino acid sequence of the polypeptide

25 coded for and where "enriched" tissue sources of mRNA are not readily available for use in constructing cDNA libraries. Such improved methods would be especially useful if they were applicable to isolating mammalian genomic clones where sparse information is available concerning amino acid sequences of the polypeptide coded for

30 by the gene sought.

#### B. Erythropoietin As A Polypeptide Of Interest

Erythropoiesis, the production of red blood

35 cells, occurs continuously throughout the human life span to offset cell destruction. Erythropoiesis is a very

AM 27 013958

AM-ITC 00453894

- 10 -

precisely controlled physiological mechanism enabling sufficient numbers of red blood cells to be available in the blood for proper tissue oxygenation, but not so many that the cells would impede circulation. The formation  
5 of red blood cells occurs in the bone marrow and is under the control of the hormone, erythropoietin.

Erythropoietin, an acidic glycoprotein of approximately 34,000 dalton molecular weight, may occur in three forms:  $\alpha$ ,  $\beta$  and asialo. The  $\alpha$  and  $\beta$  forms  
10 differ slightly in carbohydrate components, but have the same potency, biological activity and molecular weight. The asialo form is an  $\alpha$  or  $\beta$  form with the terminal carbohydrate (sialic acid) removed. Erythropoietin is present in very low concentrations in plasma when the body  
15 is in a healthy state wherein tissues receive sufficient oxygenation from the existing number of erythrocytes. This normal low concentration is enough to stimulate replacement of red blood cells which are lost normally through aging.

The amount of erythropoietin in the circulation  
20 is increased under conditions of hypoxia when oxygen transport by blood cells in the circulation is reduced. Hypoxia may be caused by loss of large amounts of blood through hemorrhage, destruction of red blood cells by  
25 over-exposure to radiation, reduction in oxygen intake due to high altitudes or prolonged unconsciousness, or various forms of anemia. In response to tissues undergoing hypoxic stress, erythropoietin will increase red blood cell production by stimulating the conversion  
30 of primitive precursor cells in the bone marrow into pro-erythroblasts which subsequently mature, synthesize hemoglobin and are released into the circulation as red blood cells. When the number of red blood cells in circulation is greater than needed for normal tissue oxygen  
35 requirements, erythropoietin in circulation is decreased.

See generally, Testa, et al., Exp.Hematol.,  
8(Supp. 8), 144-152 (1980); Tong, et al., J.Biol.Chem.,

AM 27 013959

AM-ITC 00453895

- 11 -

256(24), 12666-12672 (1981); Goldwasser, J.Cell.Physiol.,  
110(Supp. 1), 133-135 (1982); Finch, Blood, 60(6),  
 1241-1246 (1982); Sytowski, et al., Expt.Hematol., 8(Supp  
8), 52-64 (1980; Naughton, Ann.Clin.Lab.Sci., 13(5),  
 5 432-438 (1983); Weiss, et al., Am.J.Vet.Res.,  
44(10), 1832-1835 (1983); Lappin, et al., Exp.Hematol.,  
11(7), 661-666 (1983); Baciú, et al., Ann.N.Y.Acad.Sci.,  
414, 66-72 (1983); Murphy, et al., Acta.Haematologica  
Japonica, 46(7), 1380-1396 (1983); Dessypris, et al.,  
 10 Brit.J.Haematol., 56, 295-306 (1984); and, Emmanouel, et  
 al., Am.J.Physiol., 247 (1 Pt 2), F168-76 (1984).

Because erythropoietin is essential in the pro-  
 cess of red blood cell formation, the hormone has poten-  
 tial useful application in both the diagnosis and the  
 15 treatment of blood disorders characterized by low or  
 defective red blood cell production. See, generally,  
 Pennathur-Das, et al., Blood, 63(5), 1168-71 (1984) and  
 Haddy, Am.Jour.Ped.Hematol./Oncol., 4, 191-196, (1982)  
 relating to erythropoietin in possible therapies for  
 20 sickle cell disease, and Eschbach, et al. J.Clin.Invest.,  
74(2), pp. 434-441, (1984), describing a therapeutic  
 regimen for uremic sheep based on in vivo response to  
 erythropoietin-rich plasma infusions and proposing a  
 dosage of 10 U EPO/kg per day for 15-40 days as correc-  
 25 tive of anemia of the type associated with chronic renal  
 failure. See also, Krane, Henry Ford Hosp.Med.J., 31(3),  
 177-181 (1983).

It has recently been estimated that the availa-  
 bility of erythropoietin in quantity would allow for  
 30 treatment each year of anemias of 1,600,000 persons in  
 the United States alone. See, e.g., Morrison,  
 "Bioprocessing in Space -- an Overview", pp. 557-571 in  
 The World Biotech Report 1984, Volume 2:USA, (Online  
 Publications, New York, N.Y. 1984). Recent studies have  
 35 provided a basis for projection of efficacy of erythro-

AM 27 013960

AM-ITC 00453896

- 12 -

poietin therapy in a variety of disease states, disorders and states of hematologic irregularity: Vedovato, et al., Acta.Haematol, 71, 211-213 (1984) (beta-thalassemia); Vichinsky, et al., J.Pediatr., 105(1), 15-21 (1984) (cystic fibrosis); Cotes, et al., Brit.J.Obstet.Gyneacol., 90(4), 304-311 (1983) (pregnancy, menstrual disorders); Haga, et al., Acta.Pediatr.Scand., 72, 827-831 (1983) (early anemia of prematurity); Claus-Walker, et al., Arch.Phys.Med.Rehabil., 65, 370-374 (1984) (spinal cord injury); Dunn, et al., Eur.J.Appl.Physiol., 52, 178-182 (1984) (space flight); Miller, et al., Brit.J.Haematol., 52, 545-590 (1982) (acute blood loss); Udupa, et al., J.Lab.Clin.Med., 103(4), 574-580 and 581-588 (1984); and Lipschitz, et al., Blood, 63(3), 502-509 (1983) (aging); and Dainiak, et al., Cancer, 51(6), 1101-1106 (1983) and Schwartz, et al., Otolaryngol., 109, 269-272 (1983) (various neoplastic disease states accompanied by abnormal erythropoiesis).

Prior attempts to obtain erythropoietin in good yield from plasma or urine have proven relatively unsuccessful. Complicated and sophisticated laboratory techniques are necessary and generally result in the collection of very small amounts of impure and unstable extracts containing erythropoietin.

U.S. Letters Patent No. 3,033,753 describes a method for partially purifying erythropoietin from sheep blood plasma which provides low yields of a crude solid extract containing erythropoietin.

Initial attempts to isolate erythropoietin from urine yielded unstable, biologically inactive preparations of the hormone. U.S. Letters Patent No. 3,865,801 describes a method of stabilizing the biological activity of a crude substance containing erythropoietin recovered from urine. The resulting crude preparation containing erythropoietin purportedly retains 90% of erythropoietin activity, and is stable.

AM 27 013961

AM-ITC 00453897

- 13 -

Another method of purifying human erythropoietin from urine of patients with aplastic anemia is described in Miyake, et al., J.Biol.Chem., Vol. 252, No. 15 (August 10, 1977), pp. 5558-5564. This seven-step procedure  
 5 includes ion exchange chromatography, ethanol precipitation, gel filtration, and adsorption chromatography, and yields a pure erythropoietin preparation with a potency of 70,400 units/mg of protein in 21% yield.

U.S. Letters Patent No. 4,397,840 to Takezawa,  
 10 et al. describes methods for preparing "an erythropoietin product" from healthy human urine specimens with weakly basic ion exchangers and proposes that the low molecular weight products obtained "have no inhibitory effects against erythropoietin.

U.K. Patent Application No. 2,085,887 by  
 Sugimoto, et al., published May 6, 1982, describes a process for the production of hybrid human lymphoblastoid cells, reporting production levels ranging from 3 to 420 Units of erythropoietin per ml of suspension of cells  
 20 (distributed into the cultures after mammalian host propagation containing up to  $10^7$  cells per ml. At the highest production levels asserted to have been obtained, the rate of erythropoietin production could be calculated to be from 40 to about 4,000 Units/ $10^6$  cells/48 hours in in vitro culture following transfer of cells from in vivo  
 25 propagation systems. (See also the equivalent U.S. Letters Patent No. 4,377,513.) Numerous proposals have been made for isolation of erythropoietin from tissue sources, including neoplastic cells, but the yields have  
 30 been quite low. See, e.g., Jelkman, et al., Expt.Hematol., 11(7), 581-588 (1983); Tambourin, et al., P.N.A.S. (U.S.A.), 80, 6269-6273 (1983); Katsuoaka, et al., Gann, 74, 534-541 (1983); Hagiwara, et al., Blood, 63(4), 828-835 (1984); and Choppin, et al., Blood, 64(2),  
 35 341-347 (1984).

Other isolation techniques utilized to obtain purified erythropoietin involve immunological procedures.

AM 27 013962

AM-ITC 00453898

- 14 -

A polyclonal, serum-derived antibody directed against erythropoietin is developed by injecting an animal, preferably a rat or rabbit, with human erythropoietin. The injected human erythropoietin is recognized as a foreign antigenic substance by the immune system of the animal and elicits production of antibodies against the antigen. Differing cells responding to stimulation by the antigenic substance produce and release into circulation antibodies slightly different from those produced by other responding cells. The antibody activity remains in the serum of the animal when its blood is extracted. While unpurified serum or antibody preparations purified as a serum immunoglobulin G fraction may then be used in assays to detect and complex with human erythropoietin, the materials suffer from a major disadvantage. This serum antibody, composed of all the different antibodies produced by individual cells, is polyclonal in nature and will complex with components in crude extracts other than erythropoietin alone.

Of interest to the background of the present invention are recent advances in the art of developing continuous cultures of cells capable of producing a single species of antibody which is specifically immunologically reactive with a single antigenic determinant of a selected antigen. See, generally, Chisholm, High Technology, Vol. 3, No. 1, 57-63 (1983). Attempts have been made to employ cell fusion and hybridization techniques to develop "monoclonal" antibodies to erythropoietin and to employ these antibodies in the isolation and quantitative detection of human erythropoietin. As one example, a report of the successful development of mouse-mouse hybridoma cell lines secreting monoclonal antibodies to human erythropoietin appeared in abstract form in Lee-Huang, Abstract No. 1463 of Fed.Proc., 41, 520 (1982). As another example, a detailed description

AM 27 013963

AM-ITC 00453899



- 15 -

of the preparation and use of a monoclonal, anti-erythropoietin antibody appears in Weiss, et al., P.N.A.S. (U.S.A.), 79, 5465-5469 (1982). See also, Sasaki, Biomed.Biochim.Acta., 42(11/12), S202-S206

5 (1983); Yanagawa, et al., Blood, 64(2), 357-364 (1984); Yanagawa, et al., J.Biol.Chem., 259(5), 2707-2710 (1984); and U.S. Letters Patent No. 4,465,624.

Also of interest to the background of the invention are reports of the immunological activity of synthetic peptides which substantially duplicate the amino acid sequence extant in naturally-occurring proteins, glycoproteins and nucleoproteins. More specifically, relatively low molecular weight polypeptides have been shown to participate in immune reactions which are similar in duration and extent to the immune reactions of physiologically significant proteins such as viral antigens, polypeptide hormones, and the like. Included among the immune reactions of such polypeptides is the provocation of the formation of specific antibodies in immunologically active animals. See, e.g., Lerner, et al., Cell, 23, 309-310 (1981); Ross, et al., Nature, 294, 654-656 (1981); Walter, et al., P.N.A.S. (U.S.A.), 77, 5197-5200 (1980); Lerner, et al., P.N.A.S. (U.S.A.), 78, 3403-3407 (1981); Walter, et al., P.N.A.S. (U.S.A.), 78, 4882-4886 (1981); Wong, et al., P.N.A.S. (U.S.A.), 78, 7412-7416 (1981); Green, et al. Cell, 28, 477-487 (1982); Nigg, et al., P.N.A.S. (U.S.A.), 79, 5322-5326 (1982); Baron, et al., Cell, 28, 395-404 (1982); Dreesman, et al., Nature, 295, 158-160 (1982); and Lerner, Scientific American, 248, No. 2, 66-74 (1983). See, also, Kaiser, et al., Science, 223, pp. 249-255 (1984) relating to biological and immunological activities of synthetic peptides which approximately share secondary structures of peptide hormones but may not share their primary structural conformation. The above studies relate, of course, to amino acid sequences of proteins other than erythro-

AM 27 013964

AM-ITC 00453900

- 16 -

poietin, a substance for which no substantial amino acid sequence information has been published. In co-owned, co-pending U.S. Patent Application Serial No. 463,724, filed February 4, 1983, by J. Egrie, published August 22, 1984 as European Patent Application No. 0 116 446, there is described a mouse-mouse hybridoma cell line (A.T.C.C. No. HB8209) which produces a highly specific monoclonal, anti-erythropoietin antibody which is also specifically immunoreactive with a polypeptide comprising the following sequence of amino acids:  
NH<sub>2</sub>-Ala-Pro-Pro-Arg-Leu-Ile-Cys-Asp-Ser-Arg-Val-Leu-Glu-Arg-Tyr-Leu-Leu-Glu-Ala-Lys-COOH.

The polypeptide sequence is one assigned to the first twenty amino acid residues of mature human erythropoietin isolated according to the method of Miyake, et al., J.Biol.Chem., 252, 5558-5564 (1977) and upon which amino acid analysis was performed by the gas phase sequencer (Applied Biosystems, Inc.) according to the procedure of Hewick, M., et al., J.Biol.Chem., 256, 7990-7997 (1981). See, also, Sue, et al., Proc. Nat. Acad. Sci. (USA), 80, pp. 3651-3655 (1983) relating to development of polyclonal antibodies against a synthetic 26-mer based on a differing amino acid sequence, and Sytowski, et al., J.Immunol. Methods, 69, pp.181-186 (1984).

While polyclonal and monoclonal antibodies as described above provide highly useful materials for use in immunoassays for detection and quantification of erythropoietin and can be useful in the affinity purification of erythropoietin, it appears unlikely that these materials can readily provide for the large scale isolation of quantities of erythropoietin from mammalian sources sufficient for further analysis, clinical testing and potential wide-ranging therapeutic use of the substance in treatment of, e.g., chronic kidney disease wherein diseased tissues fail to sustain production of erythropoietin. It is consequently projected in the art that

AM 27 013965

AM-ITC 00453901

- 17 -

the best prospects for fully characterizing mammalian erythropoietin and providing large quantities of it for potential diagnostic and clinical use involve successful application of recombinant procedures to effect large  
5 scale microbial synthesis of the compound.

While substantial efforts appear to have been made in attempted isolation of DNA sequences coding for human and other mammalian species erythropoietin, none appear to have been successful. This is due principally  
10 to the scarcity of tissue sources, especially human tissue sources, enriched in mRNA such as would allow for construction of a cDNA library from which a DNA sequence coding for erythropoietin might be isolated by conventional techniques. Further, so little is known of the  
15 continuous sequence of amino acid residues of erythropoietin that it is not possible to construct, e.g., long polynucleotide probes readily capable of reliable use in DNA/DNA hybridization screening of cDNA and especially genomic DNA libraries. Illustratively, the twenty amino  
20 acid sequence employed to generate the above-named monoclonal antibody produced by A.T.C.C. No. HB8209 does not admit to the construction of an unambiguous, 60 base oligonucleotide probe in the manner described by Anderson, et al., supra. It is estimated that the human  
25 gene for erythropoietin may appear as a "single copy gene" within the human genome and, in any event, the genetic material coding for human erythropoietin is likely to constitute less than 0.00005% of total human genomic DNA which would be present in a genomic library.

30 To date, the most successful of known reported attempts at recombinant-related methods to provide DNA sequences suitable for use in microbial expression of isolatable quantities of mammalian erythropoietin have fallen far short of the goal. As an example, Farber, et  
35 al. Exp.Hematol., 11. Supp. 14, Abstract 101 (1983) report the extraction of mRNA from kidney tissues of

AM 27 013966

AM-ITC 00453902

- 18 -

phenylhydrazine-treated baboons and the injection of the mRNA into Xenopus laevis oocytes with the rather transitory result of in vitro production of a mixture of "translation products" which included among them

5 displaying biological properties of erythropoietin. More recently, Farber, et al., Blood, 62, No. 5, Supp. No. 1, Abstract 392, at page 122a (1983) reported the in vitro translation of human kidney mRNA by frog oocytes. The resultant translation product mixture was estimated to

10 include on the order of 220 mU of a translation product having the activity of erythropoietin per microgram of injected mRNA. While such levels of in vitro translation of exogenous mRNA coding for erythropoietin were acknowledged to be quite low (compared even to the prior

15 reported levels of baboon mRNA translation into the sought-for product) it was held that the results confirm the human kidney as a site of erythropoietin expression, allowing for the construction of an enriched human kidney cDNA library from which the desired gene might be iso-

20 lated. [See also, Farber, Clin.Res., 31(4), 769A (1983).]

Since the filing of U.S. Patent Application Serial Nos. 561,024 and 582,185, there has appeared a single report of the cloning and expression of what is

25 asserted to have been human erythropoietin cDNA in E.coli. Briefly put, a number of cDNA clones were inserted into E.coli plasmids and  $\beta$ -lactamase fusion products were noted to be immunoreactive with a monoclonal antibody to an unspecified "epitope" of human erythropoietin. See, Lee-Huang, Proc. Nat. Acad. Sci. (USA),

30 81, pp. 2708-2712 (1984).

#### BRIEF SUMMARY

35 The present invention provides, for the first time, novel purified and isolated polypeptide products

AM 27 013967

AM-ITC 00453903

- 19 -

having part or all of the primary structural conformation (i.e., continuous sequence of amino acid residues) and one or more of the biological properties (e.g., immunological properties and in vivo and in vitro biological activity) of naturally-occurring erythropoietin, including allelic variants thereof. These polypeptides are also uniquely characterized by being the product of procaryotic or eucaryotic host expression (e.g., by bacterial, yeast and mammalian cells in culture) of exogenous DNA sequences obtained by genomic or cDNA cloning or by gene synthesis. Products of microbial expression in vertebrate (e.g., mammalian and avian) cells may be further characterized by freedom from association with human proteins or other contaminants which may be associated with erythropoietin in its natural mammalian cellular environment or in extracellular fluids such as plasma or urine. The products of typical yeast (e.g., Saccharomyces cerevisiae) or procaryote (e.g., E.coli) host cells are free of association with any mammalian proteins. Depending upon the host employed, polypeptides of the invention may be glycosylated with mammalian or other eucaryotic carbohydrates or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue (at position -1).

Novel glycoprotein products of the invention include those having a primary structural conformation sufficiently duplicative of that of a naturally-occurring (e.g., human) erythropoietin to allow possession of one or more of the biological properties thereof and having an average carbohydrate composition which differs from that of naturally-occurring (e.g., human) erythropoietin.

Vertebrate (e.g., COS-1 and CHO) cells provided by the present invention comprise the first cells ever available which can be propagated in vitro continuously and which upon growth in culture are capable of producing

AM 27 013968

AM-ITC 00453904

- 20 -

in the medium of their growth in excess of 100U (preferably in excess of 500U and most preferably in excess of 1,000 to 5,000U) of erythropoietin per  $10^6$  cells in 48 hours as determined by radioimmunoassay.

5 Also provided by the present invention are synthetic polypeptides wholly or partially duplicative of continuous sequences of erythropoietin amino acid residues which are herein for the first time elucidated. These sequences, by virtue of sharing primary, secondary  
10 or tertiary structural and conformational characteristics with naturally-occurring erythropoietin may possess biological activity and/or immunological properties in common with the naturally-occurring product such that they may be employed as biologically active or immunolo-  
15 gical substitutes for erythropoietin in therapeutic and immunological processes. Correspondingly provided are monoclonal and polyclonal antibodies generated by standard means which are immunoreactive with such polypeptides and, preferably, also immunoreactive with  
20 naturally-occurring erythropoietin.

Illustrating the present invention are cloned DNA sequences of monkey and human species origins and polypeptide sequences suitably deduced therefrom which represent, respectively, the primary structural confor-  
25 mation of erythropoietins of monkey and human species origins.

Also provided by the present invention are novel biologically functional viral and circular plasmid DNA vectors incorporating DNA sequences of the invention and  
30 microbial (e.g., bacterial, yeast and mammalian cell) host organisms stably transformed or transfected with such vectors. Correspondingly provided by the invention are novel methods for the production of useful polypeptides comprising cultured growth of such transformed or  
35 transfected microbial hosts under conditions facilitative of large scale expression of the exogenous, vector-borne

AM 27 013969

AM-ITC 00453905

- 21 -

DNA sequences and isolation of the desired polypeptides from the growth medium, cellular lysates or cellular membrane fractions.

Isolation and purification of microbially

5 expressed polypeptides provided by the invention may be by conventional means including, e.g., preparative chromatographic separations and immunological separations involving monoclonal and/or polyclonal antibody preparations.

10 Having herein elucidated the sequence of amino acid residues of erythropoietin, the present invention provides for the total and/or partial manufacture of DNA sequences coding for erythropoietin and including such advantageous characteristics as incorporation of codons  
15 "preferred" for expression by selected non-mammalian hosts, provision of sites for cleavage by restriction endonuclease enzymes and provision of additional initial, terminal or intermediate DNA sequences which facilitate construction of readily expressed vectors. Correspondingly, the present invention provides for manufacture  
20 (and development by site specific mutagenesis of cDNA and genomic DNA) of DNA sequences coding for microbial expression of polypeptide analogs or derivatives of erythropoietin which differ from naturally-occurring  
25 forms in terms of the identity or location of one or more amino acid residues (i.e., deletion analogs containing less than all of the residues specified for EPO and/or substitution analogs wherein one or more residues specified are replaced by other residues and/or addition  
30 analogs wherein one or more amino acid residues is added to a terminal or medial portion of the polypeptide); and which share some or all the properties of naturally-occurring forms.

Novel DNA sequences of the invention include all  
35 sequences useful in securing expression in procaryotic or eucaryotic host cells of polypeptide products having at

AM 27 013970

AM-ITC 00453906

- 22 -

least a part of the primary structural conformation and one or more of the biological properties of erythropoietin which are comprehended by: (a) the DNA sequences set out in Tables V and VI herein or their complementary  
5 strands; (b) DNA sequences which hybridize (under hybridization conditions such as illustrated herein or more stringent conditions) to DNA sequences defined in (a) or fragments thereof; and (c) DNA sequences which, but for the degeneracy of the genetic code, would hybridize to  
10 DNA sequences defined in (a) and (b) above. Specifically comprehended in part (b) are genomic DNA sequences encoding allelic variant forms of monkey and human erythropoietin and/or encoding other mammalian species of erythropoietin. Specifically comprehended by part (c)  
15 are manufactured DNA sequences encoding EPO, EPO fragments and EPO analogs which DNA sequences may incorporate codons facilitating translation of messenger RNA in non-vertebrate hosts.

Comprehended by the present invention is that  
20 class of polypeptides coded for by portions of the DNA complement to the top strand human genomic DNA sequence of Table VI herein, i.e., "complementary inverted proteins" as described by Tramontano, et al., Nucleic Acids Research, 12, pp. 5049-5059 (1984).

25 Also comprehended by the invention are pharmaceutical compositions comprising effective amounts of polypeptide products of the invention together with suitable diluents, adjuvants and/or carriers which allow for provision of erythropoietin therapy, especially in  
30 the treatment of anemic disease states and most especially such anemic states as attend chronic renal failure.

Polypeptide products of the invention may be "labelled" by covalent association with a detectable  
35 marker substance (e.g., radiolabelled with <sup>125</sup>I) to provide reagents useful in detection and quantification of

AM 27 013971

AM-ITC 00453907



- 23 -

erythropoietin in solid tissue and fluid samples such as blood or urine. DNA products of the invention may also be labelled with detectable markers (such as radiolabels and non-isotopic labels such as biotin) and employed in DNA hybridization processes to locate the erythropoietin gene position and/or the position of any related gene family in the human, monkey and other mammalian species chromosomal map. They can also be used for identifying the erythropoietin gene disorders at the DNA level and used as gene markers for identifying neighboring genes and their disorders.

As hereinafter described in detail, the present invention further provides significant improvements in methods for detection of a specific single stranded polynucleotide of unknown sequence in a heterogeneous cellular or viral sample including multiple single-stranded polynucleotides where

(a) a mixture of labelled single-stranded polynucleotide probes is prepared having uniformly varying sequences of bases, each of said probes being potentially specifically complementary to a sequence of bases which is putatively unique to the polynucleotide to be detected,

(b) the sample is fixed to a solid substrate,

(c) the substrate having the sample fixed thereto is treated to diminish further binding of polynucleotides thereto except by way of hybridization to polynucleotides in said sample,

(d) the treated substrate having the sample fixed thereto is transitorily contacted with said mixture of labelled probes under conditions facilitative of hybridization only between totally complementary polynucleotides, and,

(e) the specific polynucleotide is detected by monitoring for the presence of a hybridization reaction between it and a totally complementary probe within said

AM 27 013972

AM-ITC 00453908

- 24 -

mixture of labelled probes, as evidenced by the presence of a higher density of labelled material on the substrate at the locus of the specific polynucleotide in comparison to a background density of labelled material resulting from non-specific binding of labelled probes to the substrate.

The procedures are especially effective in situations dictating use of 64, 128, 256, 512, 1024 or more mixed polynucleotide probes having a length of 17 to 20 bases in DNA/DNA or RNA/RNA or DNA/RNA hybridizations.

As described infra, the above-noted improved procedures have illustratively allowed for the identification of cDNA clones coding for erythropoietin of monkey species origins within a library prepared from anemic monkey kidney cell mRNA. More specifically, a mixture of 128 uniformly varying 20-mer probes based on amino acid sequence information derived from sequencing fractions of human erythropoietin was employed in colony hybridization procedures to identify seven "positive" erythropoietin cDNA clones within a total of 200,000 colonies. Even more remarkably, practice of the improved procedures of the invention have allowed for the rapid isolation of three positive clones from within a screening of 1,500,000 phage plaques constituting a human genomic library. This was accomplished through use of the above-noted mixture of 128 20-mer probes together with a second set of 128 17-mer probes based on amino acid analysis of a different continuous sequence of human erythropoietin.

The above-noted illustrative procedures constitute the first known instance of the use of multiple mixed oligonucleotide probes in DNA/DNA hybridization processes directed toward isolation of mammalian genomic clones and the first known instance of the use of a mixture of more than 32 oligonucleotide probes in the isolation of cDNA clones.

AM 27 013973

AM-ITC 00453909

- 25 -

Numerous aspects and advantages of the invention will be apparent to those skilled in the art upon consideration of the following detailed description which provides illustrations of the practice of the invention in its presently preferred embodiments. *Insert - Paul Andt.*

#### DETAILED DESCRIPTION

According to the present invention, DNA sequences encoding part or all of the polypeptide sequence of human and monkey species erythropoietin (hereafter, at times, "EPO") have been isolated and characterized. Further, the monkey and human origin DNA has been made the subject of eucaryotic and procaryotic expression providing isolatable quantities of polypeptides displaying biological (e.g., immunological) properties of naturally-occurring EPO as well as both in vivo and in vitro biological activities of EPO.

The DNA of monkey species origins was isolated from a cDNA library constructed with mRNA derived from kidney tissue of a monkey in a chemically induced anemic state and whose serum was immunologically determined to include high levels of EPO compared to normal monkey serum. The isolation of the desired cDNA clones containing EPO encoding DNA was accomplished through use of DNA/DNA colony hybridization employing a pool of 128 mixed, radiolabelled, 20-mer oligonucleotide probes and involved the rapid screening of 200,000 colonies. Design of the oligonucleotide probes was based on amino acid sequence information provided by enzymatic fragmentation and sequencing a small sample of human EPO.

The DNA of human species origins was isolated from a human genomic DNA library. The isolation of clones containing EPO-encoding DNA was accomplished through DNA/DNA plaque hybridization employing the above-noted pool of 128 mixed 20-mer oligonucleotide probes and

AM 27 013974

AM-ITC 00453910

- 26 -

a second pool of 128 radiolabelled 17-mer probes whose sequences were based on amino acids sequence information obtained from a different enzymatic human EPO fragment.

Positive colonies and plaques were verified by  
5 means of dideoxy sequencing of clonal DNA using a subset of 16 sequences within the pool of 20-mer probes and selected clones were subjected to nucleotide sequence analysis resulting in deduction of primary structural conformation of the EPO polypeptides encoded thereby.  
10 The deduced polypeptide sequences displayed a high degree of homology to each other and to a partial sequence generated by amino acid analysis of human EPO fragments.

A selected positive monkey cDNA clone and a selected positive human genomic clone were each inserted  
15 in a "shuttle" DNA vector which was amplified in E.coli and employed to transfect mammalian cells in culture. Cultured growth of transfected host cells resulted in culture medium supernatant preparations estimated to contain as much as 3000 mU of EPO per ml of culture fluid.

20 The following examples are presented by way of illustration of the invention and are specifically directed to procedures carried out prior to identification of EPO encoding monkey cDNA clones and human genomic clones, to procedures resulting in such identification, and to the sequencing, development of  
25 expression systems and immunological verification of EPO expression in such systems.

More particularly, Example 1 is directed to amino acid sequencing of human EPO fragments and construction of mixtures of radiolabelled probes based on  
30 the results of this sequencing. Example 2 is generally directed to procedures involved in the identification of positive monkey cDNA clones and thus provides information concerning animal treatment and preliminary radioimmunoassay (RIA) analysis of animal sera. Example 3 is  
35 directed to the preparation of the cDNA library, colony

AM 27 013975

AM-ITC 00453911

- 27 -

hybridization screening and verification of positive clones, DNA sequencing of a positive cDNA clone and the generation of monkey EPO polypeptide primary structural conformation (amino acid sequence) information. Example 4 is directed to procedures involved in the identification of positive human genomic clones and thus provides information concerning the source of the genomic library, plaque hybridization procedures and verification of positive clones. Example 5 is directed to DNA sequencing of a positive genomic clone and the generation of human EPO polypeptide amino acid sequence information including a comparison thereof to the monkey EPO sequence information. Example 6 is directed to procedures for construction of a vector incorporating EPO-encoding DNA derived from a positive monkey cDNA clone, the use of the vector for transfection of COS-1 cells and cultured growth of the transfected cells. Example 7 is directed to procedures for construction of a vector incorporating EPO-encoding DNA derived from a positive human genomic clone, the use of the vector for transfection of COS-1 cells and the cultured growth of the transfected cells. Example 8 is directed to immunoassay procedures performed on media supernatants obtained from the cultured growth of transfected cells according to Example 6 and 7. Example 9 is directed to in vitro and in vivo biological activity of microbially expressed EPO of Examples 6 and 7.

Example 10 is directed to a development of mammalian host expression systems for monkey species EPO cDNA and human species genomic DNA involving Chinese hamster ovary ("CHO") cells and to the immunological and biological activities of products of these expression systems as well as characterization of such products. Example 11 is directed to the preparation of manufactured genes encoding human species EPO and EPO analogs, which genes include a number of preference codons for

AM 27 013976

AM-ITC 00453912

- 28 -

expression in E.coli and yeast host cells, and to expression systems based thereon. Example 12 relates to the immunological and biological activity profiles of expression products of the systems of Example 11.

5

EXAMPLE 1

A. Human EPO Fragment Amino Acid Sequencing

Human EPO was isolated from urine and subjected  
10 to tryptic digestion resulting in the development and isolation of 17 discrete fragments in quantities approximating 100-150 picomoles.

Fragments were arbitrarily assigned numbers and were analyzed for amino acid sequence by microsequence  
15 analysis using a gas phase sequencer (Applied Biosystems) to provide the sequence information set out in Table I, below, wherein single letter codes are employed and "x" designates a residue which was not unambiguously determined.

20

25

30

35

AM 27 013977

AM-ITC 00453913

- 29 -

TABLE I

<u>Fragment No.</u>		<u>Sequence Analysis Result</u>
5	T4a	A-P-P-R
	T4b	G-K-L-K
	T9	A-L-G-A-Q-K
	T13	V-L-E-R
	T16	A-V-S-G-L-R
10	T18	L-F-R
	T21	K-L-F-R
	T25	Y-L-L-E-A-K
	T26a	L-I-C-D-S-R
	T26b	L-Y-T-G-E-A-C-R
15	T27	T-I-T-A-D-T-F-R
	T28	E-A-I-S-P-P-D-A-A-M-A-A-P-L-R
	T30	E-A-E-X-I-T-T-G-X-A-E-H-X-S-L- N-E-X-I-T-V-P
	T31	V-Y-S-N-F-L-R
	T33	S-L-T-T-L-L-R
20	T35	V-N-F-Y-A-W-K
	T38	G-Q-A-L-L-V-X-S-S-Q-P-W- E-P-L-Q-L-H-Y-D-K
25		
30		
35		

AM 27 013978

AM-ITC 00453914

- 30 -

B. Design and Construction of  
Oligonucleotide Probe Mixtures

The amino acid sequences set out in Table I were reviewed in the context of the degeneracy of the genetic code for the purpose of ascertaining whether mixed probe procedures could be applied to DNA/DNA hybridization procedures on cDNA and/or genomic DNA libraries. This analysis revealed that within Fragment No. T35 there existed a series of 7 amino acid residues (Val-Asn-Phe-Tyr-Ala-Trp-Lys) which could be uniquely characterized as encoded for by one of 128 possible DNA sequences spanning 20 base pairs. A first set of 128 20-mer oligonucleotides was therefore synthesized by standard phosphoramidite methods (See, e.g., Beaucage, et al., Tetrahedron Letters, 22, pp. 1859-1862 (1981) on a solid support according to the sequence set out in Table II, below.

TABLE II

Residue	- Val	- Asn	Phe	Tyr	Ala	Trp	Lys	
3'	CAA	TTG	AAG	ATG	CGA	ACC	TT	- 5'
	T	A	A	A	T			
	G				G			
	C				C			

Further analysis revealed that within fragment No. T38 there existed a series of 6 amino acid residues (Gln-Pro-Trp-Glu-Pro-Leu) on the basis of which there could be prepared a pool of 128 mixed oligonucleotide 17-mer probes as set out in Table III, below.

TABLE III

Residue	- Gln	Pro	Trp	Glu	Pro	Leu	
3'	GTT	GGA	ACC	CTT	GGA	GA	- 5'
	C	T		C	T	A	
		G			G		
		C			C		

AM 27 013979

AM-ITC 00453915



- 31 -

Oligonucleotide probes were labelled at the 5' end with gamma -  $^{32}\text{P}$ -ATP, 7500-8000 Ci/mmol (ICN) using  $\text{T}_4$  polynucleotide kinase (NEN).

5

EXAMPLE 2A. Monkey Treatment Procedures [and RIA Analysis] Pne

Female Cynomolgus monkeys Macaca fascicularias (2.5-3 kg, 1.5-2 years old) were treated subcutaneously with a pH 7.0 solution of phenylhydrazine hydrochloride at a dosage level of 12.5 mg/kg on days 1, 3 and 5. The hematocrit was monitored prior to each injection. On day 7, or whenever the hematocrit level fell below 25% of the initial level, serum and kidneys were harvested after administration of 25 mg/kg doses of ketamine hydrochloride. Harvested materials were immediately frozen in liquid nitrogen and stored at  $-70^\circ\text{C}$ .

B. RIA for EPO

Radioimmunoassay procedures applied for quantitative detection of EPO in samples were conducted according to the following procedures:

An erythropoietin standard or unknown sample was incubated together with antiserum for two hours at  $37^\circ\text{C}$ . After the two hour incubation, the sample tubes were cooled on ice,  $^{125}\text{I}$ -labelled erythropoietin was added, and the tubes were incubated at  $0^\circ\text{C}$  for at least 15 more hours. Each assay tube contained 500  $\mu\text{l}$  of incubation mixture consisting of 50  $\mu\text{l}$  of diluted immune sera, 10,000 cpm of  $^{125}\text{I}$ -erythropoietin, 5  $\mu\text{l}$  trasylol and 0-250  $\mu\text{l}$  of either EPO standard or unknown sample, with PBS containing 0.1% BSA making up the remaining volume. The antiserum used was the second test bleed of a rabbit

35

AM 27 013980

AM-ITC 00453916

- 32 -

immunized with a 1% pure preparation of human urinary erythropoietin. The final antiserum dilution on the assay was adjusted so that the antibody-bound  $^{125}\text{I}$ -EPO did not exceed 10-20% of the input total counts. In general, this corresponded to a final antiserum dilution of from 1:50,000 to 1:100,000.

The antibody-bound  $^{125}\text{I}$ -erythropoietin was precipitated by the addition of 150  $\mu\text{l}$  Staph A. After a 40 min. incubation, the samples were centrifuged and the pellets were washed two times with 0.75 ml 10 mM Tris-HCl pH 8.2 containing 0.15M NaCl, 2mM EDTA, and 0.05% Triton X-100. The washed pellets were counted in a gamma counter to determine the percent of  $^{125}\text{I}$ -erythropoietin bound. Counts bound by pre-immune sera were subtracted from all final values to correct for nonspecific precipitation. The erythropoietin content of the unknown samples was determined by comparison to the standard curve.

The above procedure was applied to monkey serum obtained in Part A, above, as well as to the untreated monkey serum. Normal serum levels were assayed to contain approximately 36 mU/ml while treated monkey serum contained from 1000 to 1700 mU/ml.

### 25 EXAMPLE 3

#### A. Monkey cDNA Library Construction

Messenger RNA was isolated from normal and anemic monkey kidneys by the guanidinium thiocyanate procedure of Chirgwin, et al., Biochemistry, 18, p. 5294 (1979) and poly (A)<sup>+</sup> mRNA was purified by two runs of oligo(dT)-cellulose column chromatography as described at pp. 197-198 in Maniatis, et al., "Molecular Cloning, A Laboratory Manual" (Cold Springs Harbor Laboratory, Cold Springs, Harbor, N.Y., 1982). The cDNA library was constructed according to a modification of the general pro-

AM 27 013981

AM-ITC 00453917

- 33 -

cedures of Okayama, et al., Mol. and Cell.Biol., 2, pp. 161-170 (1982). The key features of the presently preferred procedures were as follows: (1) pUC8 was used as the sole vector, cut with PstI and then tailed with  
 5 oligo dT of 60-80 bases in length; (2) HincII digestion was used to remove the oligo dT tail from one end of the vector; (3) first strand synthesis and oligo dG tailing was carried out according to the published procedure; (4) BamHI digestion was employed to remove the oligo dG tail  
 10 from one end of the vector; and (5) replacement of the RNA strand by DNA was in the presence of two linkers (GATCTAAAGACCGTCCCCCCCC and ACGGTCITTA) in a three-fold molar excess over the oligo dG tailed vector.

15 B. Colony Hybridization Procedures For  
Screening Monkey cDNA Library

Transformed E.coli were spread out at a density of 9000 colonies per 10 x 10 cm plate on nutrient plates containing 50 micrograms/ml Ampicillin. GeneScreen  
 20 filters (New England Nuclear Catalog No. NEF-972) were pre-wet on a BHI-CAM plate (Bacto brain heart infusion 37 g/L, Casamino acids 2 g/L and agar 15 g/L, containing 500 micrograms/ml Chloramphenicol) and were used to lift the colonies off the plate. The colonies were grown in the  
 25 same medium for 12 hours or longer to amplify the plasmid copy numbers. The amplified colonies (colony side up) were treated by serially placing the filters over 2 pieces of Whatman 3 MM paper saturated with each of the following solutions:

- 30 (1) 50 mM glucose - 25 mM Tris-HCl (pH 8.0) - 10 mM EDTA (pH 8.0) for five minutes;  
 (2) 0.5 M NaOH for ten minutes; and  
 (3) 1.0 M Tris-HCl (pH 7.5) for three minutes.  
 The filters were then air dried in a vacuum over  
 35 at 80°C for two hours.

The filters were then subjected to Proteinase K

AM 27 013982

- 34 -

digestion through treatment with a solution containing 50 micrograms/ml of the protease enzyme in Buffer K [0.1M Tris-HCl (pH 8.0) - 0.15M NaCl - 10 mM EDTA (pH 8.2) - 0.2% SDS]. Specifically, 5 ml of the solution was added to each filter and the digestion was allowed to proceed at 55°C for 30 minutes, after which the solution was removed.

The filters were then treated with 4 ml of a prehybridization buffer (5 x SSPE - 0.5% SDS - 100 micrograms/ml SS E.coli DNA - 5 x BFP). The prehybridization treatment was carried out at 55°C, generally for 4 hours or longer, after which the prehybridization buffer was removed.

The hybridization process was carried out in the following manner. To each filter was added 3 ml of hybridization buffer (5 x SSPE - 0.5% SDS - 100 micrograms/ml yeast tRNA) containing 0.025 picomoles of each of the 128 probe sequences of Table II (the total mixture being designated the EPV mixture) and the filters were maintained at 48°C for 20 hours. This temperature was 2°C less than the lowest of the calculated dissociation temperatures (Td) determined for any of the probes.

Following hybridization, the filters were washed three times for ten minutes on a shaker with 6 x SSC - 0.1% SDS at room temperature and washed two to three times with 6 x SSC - 1% SDS at the hybridization temperature (48°C).

Autoradiography of the filters revealed seven positive clones among the 200,000 colonies screened.

Initial sequence analysis of one of the putative monkey cDNA clones (designated clone 83) was performed for verification purposes by a modification of the procedure of Wallace, et al., Gene, 16, pp. 21-26 (1981). Briefly, plasmid DNA from monkey cDNA clone 83 was linearized by digestion with EcoRI and denatured by

Correction  
to p. 34,  
line 32  
redipast

AM 27 013983

- 35 -

heating in a boiling water bath. The nucleotide sequence was determined by the dideoxy method of Sanger, et al., P.N.A.S. (U.S.A.), 74, pp. 5463-5467 (1977). A subset of the EPV mixture of probes consisting of 16 sequences was used as a primer for the sequencing reactions.

C. Monkey EPO cDNA Sequencing

Nucleotide sequence analysis of clone 83 was carried out by the procedures of Messing, Methods in Enzymology, 101, pp. 20-78 (1983). Set out in Table IV is a preliminary restriction map analysis of the approximately 1600 base pair EcoRI/HindIII cloned fragment of clone 83. Approximate locations of restriction endonuclease enzyme recognition sites are provided in terms of number of bases 3' to the EcoRI site at the 5' end of the fragment. Nucleotide sequencing was carried out by sequencing individual restriction fragments with the intent of matching overlapping fragments. For example, an overlap of sequence information provided by analysis of nucleotides in a restriction fragment designated C113 (Sau3A at ~111/SmaI at ~324) and the reverse order sequencing of a fragment designated C73 (AluI at ~424/BstEII at ~203).

25

30

35

AM 27 013984

- 36 -

TABLE IV

	<u>Restriction Enzyme</u> <u>Recognition Site</u>	<u>Approximate Location(s)</u>
5	<u>EcoRI</u>	1
	<u>Sau3A</u>	111
	<u>SmaI</u>	180
	<u>BstEII</u>	203
	<u>SmaI</u>	324
10	<u>KpnI</u>	371
	<u>RsaI</u>	372
	<u>AluI</u>	424
	<u>PstI</u>	426
	<u>AluI</u>	430
15	<u>HpaI</u>	466
	<u>AluI</u>	546
	<u>PstI</u>	601
	<u>PvuII</u>	604
	<u>AluI</u>	605
20	<u>AluI</u>	782
	<u>AluI</u>	788
	<u>RsaI</u>	792
	<u>PstI</u>	807
	<u>AluI</u>	841
25	<u>AluI</u>	927
	<u>NcoI</u>	946
	<u>Sau3A</u>	1014
	<u>AluI</u>	1072
	<u>AluI</u>	1115
30	<u>AluI</u>	1223
	<u>PstI</u>	1301
	<u>RsaI</u>	1343
	<u>AluI</u>	1384
	<u>HindIII</u>	1449
35	<u>AluI</u>	1450
	<u>HindIII</u>	1585

AM 27 013985

- 37 -

FIGURE 5,  
comprising portions  
5A, 5B and 5C.

Sequencing of approximately 1342 base pairs (within the region spanning the Sau3A site 3' to the EcoRI site and the HindIII site) and analysis of all possible reading frames has allowed for the development of DNA and amino acid sequence information set out in ~~Table V~~. In the ~~Table~~, the putative initial amino acid residue of the amino terminal of mature EPO (as verified by correlation to the previously mentioned sequence analysis of twenty amino terminal residues) is designated by the numeral +1. The presence of a methionine-specifying ATG codon (designated -27) "upstream" of the initial amino terminal alanine residue as the first residue designated for the amino acid sequence of the mature protein is indicative of the likelihood that EPO is initially expressed in the cytoplasm in a precursor form including a 27 amino acid "leader" region which is excised prior to entry of mature EPO into circulation. Potential glycosylation sites within the polypeptide are designated by asterisks. The estimated molecular weight of the translated region was determine to be 21,117 daltons and the M.W. of the 165 residues of the polypeptide constituting mature monkey EPO was determined to be 18,236 daltons.

Fig. 6  
Prel.

AM 27 013986

AM-ITC 00453922

- 38 -

TABLE V

Translation of Monkey EPO cDNA

Sau3A  
GATCCCGCGCCCTGGACAGCGGCCCTCTCTCCAGGCCCGTGGGCTGGCCCTGCC

CGCTGAACCTCCCGGGATGAGGACTCCCGGTGTGTACCGCGCGCTAGGTGGCTGAG

-27                      -20  
Met Gly Val His Glu Cys Pro Ala Trp  
GGACCCCGCCAGGCGCGGAGATG GGG GTG CAC GAA TGT CCT GCC TGG

Leu Trp Leu Leu Ser Leu Val Ser Leu Pro Leu Gly Leu Pro  
CTG TGG CTT CTC CTG TCT CTC GTG TCG TCG CTC CCT CTG GGC CTC CCA

-1    +1                      10  
Val Pro Gly Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu  
GTC CCG GGC GCC CCA CCA CCA CGC CTC ATC TGT GAC AGC CGA GTG CTG

Glu Arg Tyr Leu Leu Glu Ala Lys Glu Ala Glu Asn Val Thr Met  
GAG AGG TAC CTC TTG GAG GCC AAG GAG GGC GAG AAT GTC ACG ATG

30                      20                      \*                      40  
Gly Cys Ser Glu Ser Cys Ser Leu Asn Glu Asn Ile Thr Val Pro  
GGC TGT TCC GAA AGC TGC AGC TTG AAT GAG AAT ATC ACC GTC CCA

AM 27 013987



- 39 -

TABLE V (continued)

Asp Thr Lys Val Asn Phe Tyr Ala Trp Lys Arg Met Glu Val Gly	50	
GAC ACC AAA GTT AAC TTC TAT GCC TGG AAG AGG ATG GAG GTC GGG		
Gln Gln Ala Val Glu Val Trp Gln Gly Leu Ala Leu Leu Ser Glu	60	70
CAG CAG GCT GTA GAA GTC TGG CAG GGC CTG GCC CTG CTC TCA GAA		
Ala Val Leu Arg Gly Gln Ala Val Leu Ala Asn Ser Ser Gln Pro	80	*
GCT GTC CTG CGG GGC CAG GCC GTG TTG GCC AAC TCT TCC CAG CCT		
Phe Glu Pro Leu Gln Leu His Met Asp Lys Ala Ile Ser Gly Leu	90	100
TTC GAG CCC CTG CAG CTG CAC ATG GAT AAA GCC ATC AGT GGC CTT		
Arg Ser Ile Thr Thr Leu Leu Arg Ala Leu Gly Ala Gln Glu Ala	110	
CGC AGC ATC ACC ACT CTG CTT CGG GCG CTG GGA GCC CAG GAA GCC		
Ile Ser Leu Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr Ile	120	130
ATC TCC CTC CCA GAT GCG GCC TCG GCT GCT CCA CTC CGA ACC ATC		
Thr Ala Asp Thr Phe Cys Lys Leu Phe Arg Val Tyr Ser Asn Phe	140	
ACT GCT GAC ACT TTC TGC AAA CTC TTC CGA GTC TAC TCC AAT TTC		

AM 27 013988

AM-ITC 00453924

- 40 -

TABLE V (continued)

150	160
Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala Cys Arg Arg	
CTC CCG GGA AAG CTG AAG CTG TAC ACG GGG GAG GCC TGC AGG AGA	
165	
Gly Asp Arg OR	
GGG GAC AGA TGA GCAGGTGGCTCCAGCTGGGCACATCCACCACCTCCCTCACCACA	
CTGCCCTGGCCACACCCCTCCCTCACCACCTCCCGAACCCCATCGAGGGGCTCTCAGCTAAG	
CGCCAGCCTGTCCCATGGACACTCCAGTSCCAGCAATGACATCTCAGGGGCCAGAGGAAC	
TGTCCAGAGCACAACTCTGAGATCTAAGGATGTCGAGGGGCCAACTTGAGGGCCAGAGC	
AGGAAGCATTGAGAGAGCAGCTTTAACTCAGGAGCAGACACAATGCAGGGGAACACCT	
GAGCTACTCGGCCACCTGCCAAAATTTGATGCAGGACACCGCTTGGAGGCCAATTACCTG	
TTTTTGCACCTACCAICAGGGACAGGATGACTGGAGAACTTAGGTGSCAAGCTGTGACTT	
CTCAAGGCCCTCACGGGCACCTCCCTTGGTGGCAGAGAGCCCTTGACACTGAGAGAAATTT	
TTGCAATCTGCAGCAGGAAAAATACGGACAGGTTTGGAGGTTGGAGGGTACTTGACAG	
GTGTGTGGGAAGCAGGGCGGTAGGGTGGAGCTGGGATCGGAGTGAGAACCCGTGAAGAG	
AGGATGGGGCTGGCCCTCTGGTTCTCGTGGGGTCCAAGCTT	
	HindIII

AM 27 013989

AM-ITC 00453925

- 41 -

Figure 5

The polypeptide sequence of ~~Table V~~ may readily be subjected to analysis for the presence of highly hydrophilic regions and/or secondary conformational characteristics indicative of potentially highly immunogenic regions by, e.g., the methods of Hopp, et al., P.N.A.S. (U.S.A.), 78, pp. 3824-3828 (1981) and Kyte et al., J.Mol.Biol., 157, pp. 105-132 (1982) and/or Chou, et al., Biochem., 13, pp. 222-245 (1974) and Advances in Enzymology, 47, pp. 45-47 (1978). Computer-assisted analysis according to the Hopp, et al. method is available by means of a program designated PEP Reference Section 6.7 made available by Intelligenetics, Inc., 124 University Avenue, Palo Alto, California. Prel

#### 15 EXAMPLE 4

##### A. Human Genomic Library

A Ch4A phage-borne human fetal liver genomic library prepared according to the procedures of Lawn, et al., Cell, 18, pp. <sup>Supra</sup>533-543 (1979) was obtained and maintained for use in a plaque hybridization assay. Prel

##### B. Plaque Hybridization Procedures For Screening Human Genomic Library

25 Phage particles were lysed and the DNAs were fixed on filters (50,000 plaques per filter) according to the procedures of Woo, Methods In Enzymology, 68, pp. 389-395 (1979) except for the use of GeneScreen Plus filters (New England Nuclear Catalog No. NEF-<sup>973</sup>976) and Prel.

30 NZYAM plates (NaCl, 5g; MgCl<sub>2</sub>-6H<sub>2</sub>O, 2 g; NZ-Amine A, 10g; yeast extract, 5g; casamino acids, 2 g; maltose; 2g; and agar, 15g per liter).

The air-dried filters were baked at 80°C for 1 hour and then digested with Proteinase K as described in Example 3, Part B. Prehybridization was carried out with a 1M NaCl - 1% SDS buffer for 55°C for 4 hours or more,

AM 27 013990

AM-ITC 00453926

- 42 -

after which the buffer was removed. Hybridization and post-hybridization washings were carried out as described in Example 3, Part B. Both the mixture of 128 20-mer probes designated EPV and the mixture of 128 17-mer probes designated EPQ (designated the EPQ mixture) were employed. Hybridization was carried out at 48°C using the EPV probe mixture. EPQ probe mixture hybridization was carried out at 46°C -- 4 degrees below the lowest calculated Td for members of the mixture. Removal of the hybridized probe for rehybridization was accomplished by boiling with 1 x SSC - 0.1% SDS for two minutes. Autoradiography of the filters revealed three positive clones (reactive with both probe mixtures) among the 1,500,000 phage plaques screened. Verification of the positive clones as being EPO-encoding was obtained through DNA sequencing and electron micrographic visualization of heteroduplex formation with the monkey cDNA of Example 3. This procedure also gave evidence of multiple introns in the genomic DNA sequence.

#### EXAMPLE 5

Nucleotide sequence analysis of one of the positive clones (designated  $\lambda$ hE1) was carried out and results obtained to date are set out in ~~Table VI~~ FIGURE 6, comprising portions 6A, 6B, 6C, 6D and 6E

AM 27 013991

AM-ITC 00453927

- 43 -

TABLE VI

AAGCTTC TGGGCTTCAGACCCAGCTACTTTGCGGAAC TACGAACCCAGGCATCTCTGAGTCTCCGCCCA  
 AGACGGGATGCCCCCAGGGAGGTGTCCGGGAGCCAGCCTT TCCAGATAGACGCTCCGCCAGTCCC  
 AAGGGTGGCGAACCGGCTGCAC TCCCCCTCCCGCGACCCAGGGCCCCGGAGCAGCCCCCATGACCCACACGC  
 ACGTCTGCAGCAGCCCCCGCTACGCCCCCGCGAGCTCAACCCAGGGCTCTTGCCCCCTGCTCTGACCCCCGG  
 GTGGCCCC TACCCCTGGGACCCCTCAGGCACACAGCCTCTCCCCCACCCCCACCCGCGCAGGCACACATG  
 CAGATAACAGCCCCGACCCCCGGCCAGACCCGXAGAGTCCC TGGGCCACCCCGGCCGCTGGCCTGCCGCTG  
 CGCCGACCCGGCTGTCTCCCGGAGCCGGACCCGGGCCACCCGGCCCCXCTCTGCTCCGACACCGCGGCC  
 CTTGACAGCCGCCCTCTCCTCTAGGCCGTGGGGCTGGCCCTGCACCCCGAGCTTCCCGGGATGAGGX  
 CCGGTGACCGCGCGCCCCCAAGTCGCTAGGGGACCCCCGGCCACGCGGGAG  
 Met Gly Val His  
 -27 -24  
 ATG GGG GTG CAC G  
 GTGAGTACTCGGGGCTGGGCGCTCCCGCGCGCCGGGTTCCTGTTTGAGCGGGGATTTAGCGCCCCGSGCT

AM 27 013992

AM-ITC 00453928





- 46 -

TABLE VI (cont'd.)

AAAAGAAAGAGAAAGAGAAATATGAGGCTGTATGGAATACATTTCATTTCACATCCTCACT  
CACTCATTTCATTTCATTTCACAAAGTCTTATTGCAATACCTTCTGTTTGCTCAGCTTGGTCTTGG  
GGCTGCTGAGGGGAGGAGGGGTGACATGGTACGCTCGACTCCAGAGTCCACTCCCTGTAG  
Val 56 60 70  
Gly Gln Gln Ala Val Glu Val Trp Gln Gln Gly Leu Ala Leu Leu Ser Glu Ala  
GTC GGG CAG CAG GGC GTA GAA GTC TGG CAG GGC CTG GCC CTG TCG GAA GCT  
Val 80 90  
Leu Arg Gly Gln Ala Leu Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu  
GTC CTG CGG GGC CAG GCC CTG TTG GTC AAC TCT TCC CAG CCG TGG GAG CCC CTG  
Gln 100  
Leu His Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu  
CAG CTG CAT GTG GAT AAA GCC GTC AGT GGC CTT GGC AGC CTC ACC ACT CTG CTT  
Arg 110 115  
Ala Leu Gly Ala Gln  
CGG GCT CTG GGA GCC CAG GTGAGTAGGAGCGGACACTTCTGCTTGGCTTCTGTAGAGGGGA  
GAAGGGTCTTGCTAAGGAGTACAGGAACGTCCGTTATTCCTTCCCTTCTGTGGCACTGCGGACCTCCT  
Lys 116 120  
Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala  
GTTTCTCTTGGCAG AAG GAA GCC ATC TCC CCT CCA GAT GCG GCC TCA GCT GCT

AM 27 013995

AM-ITC 00453931



- 47 -

TABLE VI (cont'd.)

130	Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser	140
CGA CTC CGA ACA ATC ACT GCT GAC ACT TTC CGC AAA CTC TTC CGA GTC TAC TCC		
150	Asn Phe Leu Arg Gly Lys Leu Lys Tyr Thr Gly Glu Ala Cys Arg Thr Gly	160
AAT TTC CTC CCG GGA AAG CTG AAG CTG TAC ACA GGG GAG GCC TGC AGG ACA GGG		
166	Asp Arg OP	
GAC AGA TGA CCAGGTTGTCTCACTGGGCATATCCACCACCCTCCCTCACCACATGCTTGTCGCCACA		
CCCTCCCCCGCCACTCCTGAACCCCGTCGAGGGCTCTCAGCTCAGGCCAGCCTGTCCCATGGACACTCC		
AGTGCCAGCAATGACATCTCAGGGGCCAGAGGAACCTGTSCAGAGAGCAACTCTGAGATCTAAGGATGTCAC		
AGGGCCAACTTGAAGGGCCAGAGCAGGAAGCATTCAGAGAGCAGCTTTAAACTCAGGGACAGAGCCATGC		
TGGGAAGACGCTGAGCTCACTCGGCACCCCTGC AAAATTTGATGCCAGGACAGGCTTTGGAGGGGATTTAC		
CTGTTTTCGCACCTACCATCAGGGACAGGAAGAGCTGGAGAACTTAGGTGGCAAGCTGTGACTTCTCCAGG		
TCACACGGGCATGGGCACCTCCCTTGGTGGCAAGAGCCCCCTTGACACGGGGGTGGTGGGAACCATSAAGAC		
AXGATXGGGGCTGGCCCTCGGCCTCATGTTGGGTCCCAAGTTTTGTGTTATCTCAACCTATTGACAGACTGAA		
ACACAATAIGAC		

AM 27 013996

AM-ITC 00453932

- 48 -

FIGURE 6,  
In ~~Table VI~~, the initial continuous DNA

Prel.

sequence designates a top strand of 620 bases in what is apparently an untranslated sequence immediately preceding a translated portion of the human EPO gene. More specifically, the sequence appears to comprise the 5' end of the gene which leads up to a translated DNA region coding for the first four amino acids (-27 through -24) of a leader sequence ("presequence"). Four base pairs in the sequence prior to that encoding the beginning of the leader have not yet been unambiguously determined and are therefore designated by an "X". There then follows an intron of about 639 base pairs (439 base pairs of which have been sequenced and the remaining 200 base pairs of which are designated "I.S.") and immediately preceding a codon for glutamine which has been designated as residue -23 of the translated polypeptide. The exon sequence immediately following is seen to code for amino acid residues through an alanine residue (designated as the +1 residue of the amino acid sequence of mature human EPO) to the codon specifying threonine at position +26, whereupon there follows a second intron consisting of 256 bases as specifically designated. Following this intron is an exon sequence for amino acid residues 27 through 55 and thereafter a third intron comprising 612 base pairs commences. The subsequent exon codes for residues 56 through 115 of human EPO and there then commences a fourth intron of 134 bases as specified. Following the fourth intron is an exon coding for residue Nos. 116 through 166 and a "stop" codon (TGA). Finally, Table VI identifies a sequence of 568 base pairs in what appears to be an untranslated 3' region of the human EPO gene, two base pairs of which ("X") have not yet been unambiguously sequenced.

~~Table VI~~  
Table VI thus serves to identify the primary structural conformation (amino acid sequence) of mature human EPO as including 166 specified amino acid residues

Prel.

AM 27 013997

AM-ITC 00453933

- 49 -

(estimated M.W. = 18,399). Also revealed in the ~~Table~~ <sup>Figure</sup> is the DNA sequence coding for a 27 residue leader sequence along with 5' and 3' DNA sequences which may be significant to promoter/operator functions of the human gene

5 operon. Sites for potential glycosylation of the mature human EPO polypeptide are designated in the ~~Table~~ <sup>Figure</sup> by asterisks. It is worthy of note that the specific amino acid sequence of ~~Table VI~~ <sup>Figure 6</sup> likely constitutes that of a naturally occurring allelic form of human erythropoietin.

10 Support for this position is found in the results of continued efforts at sequencing of urinary isolates of human erythropoietin which provided the finding that a significant number of erythropoietin molecules therein have a methionine at residue 126 as opposed to a serine as shown

15 in the ~~Table~~ <sup>Figure</sup>. ~~Figure 9~~ <sup>Figure 9</sup>, below, illustrates the extent of polypeptide sequence homology between human and monkey EPO. In the upper continuous line of the ~~Table~~ <sup>Figure</sup>, single letter designations are employed to represent the deduced

20 translated polypeptide sequences of human EPO commencing with residue -27 and the lower continuous line shows the deduced polypeptide sequence of monkey EPO commencing at assigned residue number -27. Asterisks are employed to highlight the sequence homologies. It should be noted

25 that the deduced human and monkey EPO sequences reveal an "additional" lysine (K) residue at (human) position 116. Cross-reference to ~~Table VI~~ <sup>Figure 6</sup> indicates that this residue is at the margin of a putative mRNA splice junction in the genomic sequence. Presence of the lysine residue in

30 the human polypeptide sequence was further verified by sequencing of a cDNA human sequence clone prepared from mRNA isolated from COS-1 cells transformed with the human genomic DNA in Example 7, infra.

35

AM 27 013998

AM-ITC 00453934